Artificial Red Cells (Hemoglobin-vesicles) as a Cellular-type Hemoglobin-based Oxygen Carrier for Ve

来源 :BIT`s 1st Annual International Symposium of Hematology-2012( | 被引量 : 0次 | 上传用户:zhang3862066
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
  The most abundant protein in blood is hemoglobin (Hb, 12-15 g/dL in blood).This fact indicates that oxygen transport is the most crucial for life activity.Hb is compartmentalized in red blood cells (RBCs), and the intracellular Hb concentration is 35 g/dL.In spite of its abundance in blood, Hb becomes toxic once it is released from RBCs.Hemoglobin-vesicles (HbV) are artificial oxygen carriers that mimic the cellular structure of RBCs to replace the blood transfusion.In contrast to other liposomal products containing antifungal or anticancer drugs, one injection of HbV in place of a blood transfusion is estimated as equivalent to a massive dose, such as several hundred milliliters or a few liters of normal blood contents.The fluid must therefore contain a sufficient amount of Hb, the binding site of oxygen, to carry oxygen like blood.Encapsulation of Hb can shield various toxic effects of molecular Hbs.On the other hand,the liposomal structure, surface property for biocompatibility, the balance between the stability (during storage and circulation in blood) and instability (for the prompt degradation in RES) must be considered to establish an optimal transfusion alternative.HbV is much smaller than RBC (250 vs.8000 nm), but it recreates the functions ofRBCs;(i) The oxygen-unloading of HbV is slower than that of a cell-free Hb solution;(ii) The colloid osmotic pressure is zero.For a massive dosage,HbV has to be co-injected with or suspended in a plasma substitute such as albumin;(iii) The viscosity of HbV is adjustable to that of blood;(iv) HbV is finally captured by RES, and then degraded and excreted promptly;(v) Coencapsulation of an allosteric effector regulates oxygen-affinity;(vi) Hemolysis is minimal during circulation and the lipid bilayer membrane prevents a direct contact of Hb and vasculature;(vii) Reaction of NO is retarded by an intracellular diffusion barrier, and HbV does not induce vasoconstriction.The obvious advantages of HbV are that it is pathogen free and blood type antigen free;moreover, it can withstand long-term storage for stockpiling.HbV has a variety of potential applications not only as a transfusion alternative but also as an oxygen or CO therapeutic fluid that cannot be attained by the present RBC transfusion.
其他文献
Antithrombotic therapy related thrombocytopenia has been extensively described concerning heparin and ticlopidine therapy.Clopidogrel is frequently associated with thrombotic thrombocytopenic purpura
会议
Heterozygous Factor Ⅴ Leiden, the most common inherited thrombotic disorder with an estimated incidence of about 5% in Caucasian population, poses a moderate risk of first venous thromboembolic (VTE)
会议
In order to improve clinical practice it is important to analyze usual daily practices.Patients admitted to Internal Medicine wards are mostly over 65 years old.The age related alterations in the lymp
会议
The earlier diagnosis of DIC before its overt stage is necessary for earlier treatment and for the good outcomes.In 2001, the Scientific and Standardization Committee of the International Society on T
会议
Radiotherapy is well recognised as an effective treatment modality for Hodgkin lymphoma (HL), and is an important component of treatment for favourable-risk, limited stage disease to optimise local co
会议
The biological basis for the association between Epstein-Barr virus positive Hodgkin Lymphoma (EBV+HL) and HLAclass Ⅰ alleles is unclear.HLA-class Ⅰ presents viral peptides for recognition by CD8+ T-c
会议
Multiple myeloma (MM) is a haematological disorder of clonal malignant plasma cells, accounts for 1-2% of all human cancers.Multiple myeloma is characterised by slow proliferation of the tumour cells,
会议
1.Background: Patients with multiple myeloma (MM) relapsed or refractory to current treatment options and ineligible for ASCT have a poor prognosis.Therefore new treatment options are highly needed fo
会议
Melphalan (M) 200 mg/m2 and 140mg/m2, is the standard conditioning regimen for multiple myeloma (MM) patients (pts) with normal renal function (NRF) and abnormal renal function(AbrF) respectively, und
会议
Background: To date, there is no safe and effective hemoglobin (Hb)-based oxygen carrier (HBOC) to substitute for red blood cell transfusion.Clinical application of HBOCs has been stymied by the adver
会议